Patient Exclusion Analysis Coming From FDA; Changes In Trial Recruitment Could Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Subjects with psychiatric conditions are often excluded from trials, an agency study finds, which “doesn’t seem a good thing” to Bob Temple.
You may also be interested in...
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
FDA To Be More Vigilant About Proposed Clinical Trial Exclusions
FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.